The debate over the optimal blood pressure treatment target of less than 130/80 mmHg

References

• Hay J. A British medical association lecture on the significance of a raised blood pressure. BMJ. 1931;2:43–47.
   PubMedGoogle Scholar
• Moser M. From JNC-1 to JNC-7. What have learned? Prog Cardiovasc Dis. 2006;48:303–315.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 123 mmHg. JAMA. 1967;202:1028–1034.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II. Results in patients with diastolic blood pressure 90 through 114 mmHg. JAMA. 1970;213: 1143–115.
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American heart association council on high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761–2788.
   PubMed Web of Science ®Google Scholar
• Williams B, Lindholm LH, ever B. Systolic blood pressure is all that matters. Lancet. 2008;371:2219–2221.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey R, Aronow WS, et al. ACC/AHA and other committees guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical guidelines. J Am Coll Cardiol. 2017;371:e127–e258. 2018.
   Google Scholar
• Jt W jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood pressure control (SPRINT). N Engl J Med. 2015;373:2103–2116.
   PubMed Web of Science ®Google Scholar
• Kurtkulagi O, Aktas G, Bilgin S, et al. Combined antihypertensive treatment is better than mono-therapy in hypertensive patients. Neth J Med. 2020;78: 239–2.
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective. 2017; Exp Rev Cardiovasc Ther. 15:517–523.
   Google Scholar
• Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 American college of cardiology/American heart association blood pressure guidelines. Circulation. 2018;137:109–118.
   PubMed Web of Science ®Google Scholar
• Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail patients. Circ Res. 2019;124:1045–1060.
   PubMed Web of Science ®Google Scholar
• Chrysant SG. New evidence for the diastolic J-curve effect challenges the safety of intensive blood pressure control. J Clin Hypertens. 2017;19:340–343.
   Web of Science ®Google Scholar
• Rahman F, McEvoy JW. Dangers of overly aggressive blood pressure control. Curr Cardiol Rep. 2018;20:108.
   PubMed Web of Science ®Google Scholar
• Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in the very elderly people: an investigation of the impact of frailty upon treatment effect in the hypertension in the in the very elderly Trial (HYVET) study. A double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.
   PubMed Web of Science ®Google Scholar
• Hamer M, Batty GD, Stamatakis E, et al. Hypertension awareness and psychological distress. Hypertension. 2010;56:547–550.
   PubMed Web of Science ®Google Scholar
• Carey RM, Whelton PK. Evidence for the universal blood pressure goal of < 130/80 mmHg is strong. Controversies in hypertension-pro side argument. Hypertension. 2020;76:1384–1390.
   PubMed Web of Science ®Google Scholar
• Kaul S. Evidence for the universal blood pressure goal of < 130/80 mmHg is strong. Controversies in hypertension-con side of the argument. Hypertension. 2020;76:1391–1399.
   PubMed Web of Science ®Google Scholar
• Reboussin DM, Carey RM, Whelton PK. Evidence supporting the blood pressure treatment goal of less than 130/80 mmHg. Hypertension. 2019;73:972–974.
   PubMed Web of Science ®Google Scholar
• Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613–622.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642–653.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707–719.
   PubMed Web of Science ®Google Scholar
• Bundy JD, Li C, Stuchlik F, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA. 2017;2:775–781.
   Google Scholar
• Sakima A, Satonaka H, Nishida N, et al. Optimal blood pressure target for patients with hypertension: a systematic review and meta-analysis. Hypertens Res. 2019;42:483–495.
   PubMed Web of Science ®Google Scholar
• Cooper-Dehoff RM, Gong Y, Hanberg E, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–68.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington BP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. The ACCORD study group. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). Circulation. 2011;124:1727–1736.
   PubMed Web of Science ®Google Scholar
• Sim JJ, Shi J, Kovesdy CK, et al. Impact of achieved blood pressure on mortality risk and end-stage renal disease among a large diverse hypertension population. J Am Coll Cardiol. 2014;64:588–597.
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. Current status of aggressive blood pressure control in diabetic hypertensive subjects. Am J Cardiol. 2011;107:1855–1861.
   Web of Science ®Google Scholar
• Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–615.
   PubMed Web of Science ®Google Scholar
• Yano Y, Rakugi H, Bakris GL, et al. On-treatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. Hypertension. 2017;69:220–227.
   PubMed Web of Science ®Google Scholar
• Myers MG, Kaczorowiski J, Dolovich L, et al. Cardiovascular risk in hypertension in relation to achieving blood pressure using automated office blood pressure measurement. Hypertension. 2016;68:866–872.
   PubMed Web of Science ®Google Scholar
• Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226–2237.
   PubMed Web of Science ®Google Scholar
• Saiz LC, Gorricho J, Garjon J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD010315.
   PubMed Web of Science ®Google Scholar
• Brunstrom M, Carlberg B. Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomized placebo-controlled trials. BMJ Open. 2019;9:e026686.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure control of the risk of recurrent stroke. A randomized clinical trial meta-analysis. JAMA Neurol. 2019;76:1309–1318.
   PubMed Web of Science ®Google Scholar
• Bress AP, Colantonio LD, Cooper R, et al. Potential cardiovascular disease events prevented with adoption the 2017 American college of cardiology/American heart association blood pressure guidelines. Circulation. 2019;139:24–36.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence –based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Aggressive systolic blood pressure control in older subjects: benefits and risks. Postgrad Med. 2018;130:159–165.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White MB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertens. 2014;16:14–26.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic treatment of hypertension in adults 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American college of physicians and the American Academy of family physicians. Ann Intern Med. 2017;166:430–437.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Cannon CP, Crandall J, et al. Cardiovascular disease and risk management: standards of medical care in diabetes- 2019. American diabetes association. Diabetes Care. 2019;42(Suppl. 1):S103–S123 .
   PubMedGoogle Scholar
• Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada. hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506–525.
   PubMed Web of Science ®Google Scholar
• Scientific Document Group: Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar P, et al. International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38:982–1004.
   PubMed Web of Science ®Google Scholar
• Muntner P, Whelton PK, Woodward M. A comparison of the 2017 American college of cardiology/American heart association blood pressure guideline and the 2017 American diabetes association. Diabetes and hypertension position statement for US adults with diabetes. Diabetes Care. 2018;41:2322–2329.
   PubMed Web of Science ®Google Scholar
• Del Pinto R, Grassi D, Bocale R, et al. Blood pressure profiles and cognitive function from adulthood to old age: casing a golden middle way? J Clin Med. 2021;10:3243.
   PubMed Web of Science ®Google Scholar
• Odden MC, Lee SJ, Steinman MA, et al. Deprescribing blood pressure treatment in long-term care residents. J Am Med Dir Assoc. 2021;22:2540–2546. e2.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Oparil S, Narkiewicz K, et al. The J-curve phenomenon revisited again: SPRINT outcomes target systolic blood pressure to below 120 mmHg. Blood Press. 2016;25:1–3.
   PubMed Web of Science ®Google Scholar
• Itoga NK, Tawfic DS, Montez-Rath MF, et al. Contributions of systolic and diastolic blood pressures to cardiovascular outcomes in the ALLHAT study. J Am Coll Cardiol. 2021;78:1671–1678.
   PubMed Web of Science ®Google Scholar
• Atik F, Aktas G, Kocak MZ, et al. Analysis of factors related to the blood pressure control in hypertension. J Coll Physicians Surg Pak. 2018 Atik F, A;28:423–426.
   PubMed Web of Science ®Google Scholar
• Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid and HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022;13:1–6.
   Web of Science ®Google Scholar
• Liu R, Peng Y, Wu H, et al. Uric acid to high-density lipoprotein cholesterol ratio predicts cardiovascular mortality in patients on peritoneal dialysis. Nutr Metab Cardiovasc Dis. 2021;31:113–118.
   Web of Science ®Google Scholar
• Chysant SG. Noninvasive vascular function tests for the future prediction of primary cardiovascular diseases. Hosp Pract. 2020;48:113–118.
   Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898.
   PubMed Web of Science ®Google Scholar
• Filipovsky J, Seidlerova J, Kratochvil Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients . Vol. 25. Blood Press; 2016. p. 228–234.
   Google Scholar
• Salvetti M, Paini A, Aggiusti C, et al. Unattended versus attended blood pressure measurement. Relationship with preclinical organ damage. Hypertens. 2019;73:736–742.
   PubMed Web of Science ®Google Scholar